Corbus Pharmaceuticals to Release Phase 1a Results for CRB-913 on December 11, 2025
- Clinical Trial Progress: Corbus Pharmaceuticals plans to release the Phase 1a results for CRB-913 on December 11, 2025, prior to market open, marking a significant step in the company's ongoing research efforts in oncology and obesity.
- Webcast Arrangement: On the same day at 8:00 am ET, Corbus will host a conference call and live webcast to discuss the Phase 1 data, aiming to enhance investor transparency and confidence in the company's research advancements.
- Innovative Drug Mechanism: CRB-913 is an oral small molecule CB1 inverse agonist designed to have reduced brain penetration, which is expected to lower the risk of neuropsychiatric adverse events, thus providing a safer option for obesity treatment.
- Market Potential Outlook: CRB-913 has shown a significantly lower brain penetration rate in preclinical models compared to other experimental CB1 inverse agonists, potentially opening new growth opportunities for the company in the obesity treatment market.
Trade with 70% Backtested Accuracy
Analyst Views on CRBP
About CRBP
About the author
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update
Phase 1a Study Results: Corbus Pharmaceuticals announced positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for chronic obesity management, showing safety, tolerability, and a placebo-adjusted mean weight loss of 2.9% in participants.
Upcoming Phase 1b Study: The encouraging Phase 1a results support the initiation of the CANYON-1 Phase 1b study, which will involve 240 obese, non-diabetic participants over 12 weeks to evaluate different dosing regimens.
Safety Profile: CRB-913 is designed to minimize brain penetration, addressing safety concerns associated with previous drugs in its class, and has shown to be significantly less brain-penetrant compared to competitors.
Broader Pipeline and Stock Performance: Corbus's pipeline includes other candidates like CRB-701 and CRB-601, while the company's stock has seen significant fluctuations, currently trading at $13.77, up 34.17%.
Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update
Phase 1a Study Results: Corbus Pharmaceuticals announced positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for chronic obesity management, showing safety, tolerability, and a placebo-adjusted mean weight loss of 2.9% in participants.
Upcoming Phase 1b Study: The encouraging Phase 1a results support the initiation of the CANYON-1 Phase 1b study, which will involve 240 obese, non-diabetic participants over 12 weeks to evaluate different dosing regimens.
Safety Profile: CRB-913 is designed to minimize brain penetration, addressing safety concerns associated with previous drugs in its class, and has shown to be significantly less brain-penetrant compared to competitors.
Broader Pipeline and Stock Performance: Corbus's pipeline includes other candidates like CRB-701 and CRB-601, while the company's stock has seen significant fluctuations, currently trading at $13.77, up 34.17%.
Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
